Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 13 h ago

Revolution Medicines, Inc.: BAKER BROS. ADVISORS LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Baker Bros. Advisors LP amended its Schedule 13G filing on Revolution Medicines, Inc., updating its beneficial ownership stake with the SEC under accession number 0001104659-26-128347. The filing reflects the biotech-focused investor's latest position in the clinical-stage oncology company. Schedule 13G amendments are typically filed by investors holding passive stakes of 5% or more, making the update a signal of Baker Bros.' current exposure to Revolution Medicines. The specific share count and percentage change were not disclosed in the filing headline. Investors will watch for further 13G or 13D filings to gauge whether the advisor is accumulating, holding steady, or trimming its position.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Revolution Medicines, Inc., Baker Bros. Advisors LP